文献速递肝病消化道肿瘤与早癌

免疫相关不良事件与肝细胞癌免疫检查点抑制剂治疗后结局改善相关:系统综述与荟萃分析

Immune-Related Adverse Events Are Associated With Improved Outcomes After Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2025-05-16

该系统综述与荟萃分析检索截至2024年6月的数据库,纳入24项研究共4127例接受免疫检查点抑制剂治疗的不可切除肝细胞癌患者,发现发生免疫相关不良事件与更高的客观缓解率、疾病控制率和更长的无进展生存期相关,总生存期呈延长趋势但未达统计学显著。

要点

  • 发生irAEs与客观缓解率(相对比1.73)和疾病控制率(相对比1.45)升高相关。
  • 发生irAEs与无进展生存期延长相关(合并HR 0.66),总生存期呈延长趋势但未达统计学显著(HR 0.84)。
  • 1-2级irAEs患者显示生存获益(合并HR 0.50),内分泌irAEs患者亦显示生存获益(合并HR 0.63)。

核心结论

  • 免疫相关不良事件的发生与肝细胞癌患者较好的临床结局相关,包括无进展生存期改善和客观缓解率提高。
  • 轻度免疫相关不良事件患者观察到总生存获益,而重度免疫相关不良事件患者未观察到。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Scopus、Web of Science和Central Register of Controlled Trials数据库,检索时间从建库至2024年6月。
  • 共纳入24项研究、4127例接受免疫检查点抑制剂治疗的肝细胞癌患者,采用随机效应模型进行统计分析。

主要发现

  • 在3028项研究中,24项(4127例患者)符合纳入标准。
  • 阿替利珠单抗联合贝伐珠单抗是最常见的治疗方案(10项研究)。
  • 发生irAEs与客观缓解率升高相关(合并相对比1.73;95%CI 1.36-2.21,I²=41%)。
  • 发生irAEs与疾病控制率升高相关(合并相对比1.45;95%CI 1.21-1.74,I²=74%)。
  • 发生irAEs与无进展生存期延长相关(合并HR 0.66;95%CI 0.52-0.84,I²=71%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become the first-line treatment of unresectable hepatocellular carcinoma (HCC). The prognostic value of immune-related adverse events (irAEs) in these patients remains controversial. We aimed to investigate the association between irAEs and clinical outcomes in patients with HCC treated with ICIs. METHODS: We searched the PubMed, Scopus, Web of Science, and Central Register of Controlled Trials databases for articles published from inception to June 2024, using keywords including ICI, HCC, and irAEs. Statistical analysis was performed with a random effects model. RESULTS: Of 3,028 studies, 24 (4,127 patients) met the criteria for inclusion. Atezolizumab plus bevacizumab was the most common treatment regimen (n = 10 studies). IrAEs were associated with an increased objective response rate (pooled relative ratio: 1.73; 95% confidence interval [CI]: 1.36-2.21, I 2 = 41%), a higher disease control rate (pooled relative ratio: 1.45; 95% CI: 1.21-1.74, I 2 = 74%), and longer progression-free survival (pooled hazard ratio [HR]: 0.66; 95% CI: 0.52-0.84, I 2 = 71%). There was a trend toward longer overall survival for patients with irAEs compared with those without (pooled HR: 0.84; 95% CI: 0.63-1.12, I 2 = 73%). Subgroup analysis indicated a survival benefit for patients with grade 1-2 irAEs (pooled HR: 0.50; 95% CI: 0.36-0.67, I 2 = 0%) and for those with endocrine irAEs (pooled HR: 0.63; 95% CI: 0.48-0.83, I 2 = 12%). DISCUSSION: The development of irAEs is associated with favorable clinical outcomes in HCC, including improved progression-free survival and higher objective response rate. Overall survival benefit was noted in patients with mild irAEs but not those with severe irAEs.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Hwang SY, Rezaee-Zavareh MS, Attia AM, et al. Immune-Related Adverse Events Are Associated With Improved Outcomes After Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025. PMID: 40377239. doi:10.14309/ajg.0000000000003546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。